Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cabazitaxel · 1 trial · 1 indication
rPFS is defined as the time from randomisation to radiographic progression, as assessed by the BICR per RECIST 1.1 (soft tissue) and/or PCWG3 criteria (bone), or death due to any cause.
OS is defined as the length of time from randomisation until the date of death due to any cause.
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Actinium (225Ac) zadavotide guraxetan (AZD2265 \[FPI-2265\]) |
| Arm B | ACTIVE_COMPARATOR | Investigator's choice of cabazitaxel, ARPI, or radium-223 |
| Name | Type | Description |
|---|---|---|
| Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) | DRUG | IV |
| Cabazitaxel | DRUG | IV in combination with oral prednisone/prednisolone |
| Abiraterone | DRUG | Oral in combination with prednisone/prednisolone |
| Enzalutamide | DRUG | Oral |
| Apalutamide | DRUG | Oral; Available only to participants randomized under Protocol Version 2.0; not offered to participants randomized under Protocol Version 3.0 (04 June 2026) |
| Darolutamide | DRUG | Oral; Available only to participants randomized under Protocol Version 2.0; not offered to participants randomized under Protocol Version 3.0 (04 June 2026) |
| Deutenzalutamide | DRUG | Oral; available in China only |
| Radium-223 | DRUG | IV |
Inclusion Criteria: * ≥ 18 years of age. * Diagnosis of adenocarcinoma of prostate. * Must have had prior orchiectomy and/or ongoing ADT and a castrate level of plasma/serum testosterone. * Progressive mCRPC following the most recent treatment at the time of study entry, with at least 1 metastatic ...
Cabazitaxel is a small molecule being studied for the treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC). It is currently in Phase 3 clinical development as an investigational therapy. The drug is being evaluated in patients with PSMA-positive mCRPC, a specific subtype of the disease.
Cabazitaxel is a taxane-class chemotherapy agent that works by disrupting microtubule function, which is essential for cell division. By stabilizing microtubules, it inhibits cancer cell proliferation. This mechanism is relevant in Metastatic Castration-resistant Prostate Cancer, where it is being studied as a potential treatment option.
Cabazitaxel is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with Metastatic Castration-resistant Prostate Cancer.
Cabazitaxel is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is designed to compare the drug with standard of care in patients with PSMA-positive Metastatic Castration-resistant Prostate Cancer.
Cabazitaxel is being evaluated in a Phase 3 clinical trial with the identifier NCT07611110, titled 'AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)'. This randomized, active-controlled trial is recruiting 670 male patients aged 18 years and older across multiple countries.
Yes, Cabazitaxel is also known as AZD2265. The Phase 3 clinical trial NCT07611110, which is evaluating the drug in Metastatic Castration-resistant Prostate Cancer, uses the name AZD2265 in its title. This alternative name is used by the developer AstraZeneca PLC for the same investigational compound.